Nifedipine attenuates changes in nitric oxide levels, renal oxidative stress, and nephrotoxicity induced by cyclosporine

Renal Failure

Volumn 27, Issue 4, 2005, Pages 441-450

  Chander, Vikas ^a   Chopra, Kanwaljit ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Cyclosporine A (CsA); Hemodynamic alterations; Nephrotoxicity; Nifedipine; Nitric oxide (NO)

Indexed keywords

AMINOGUANIDINE; CATALASE; CREATININE; CYCLOSPORIN A; GLUTATHIONE; MALONALDEHYDE; N(G) NITROARGININE METHYL ESTER; NIFEDIPINE; NITRATE; NITRIC OXIDE; NITRITE; PROPRANOLOL; SUPEROXIDE DISMUTASE; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEMODYNAMICS; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; MALE; MORPHOLOGY; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TISSUE LEVEL; UREA NITROGEN BLOOD LEVEL; URINE LEVEL; VASOCONSTRICTION;

ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; CYCLOSPORINE; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; LIPID PEROXIDATION; MALE; NIFEDIPINE; NITRIC OXIDE; OXIDATIVE STRESS; PROBABILITY; RANDOM ALLOCATION; RATS; RATS, WISTAR; REFERENCE VALUES; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 22244441502     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-65240     Document Type: Article

References (57)

1. Busauschina, A.; Schnuelle, P.; Van der Woude, F.J. Cyclosporine nephrotoxicity. Transplant. Proc. 2004, 36, 229S-233S.
2. Rang, D.H.; Kim, Y.G.; Andoh, T.F.; et al. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am. J. Physiol., Renal Physiol. 2001, 280, F727-F736.
3. Shihab, F.S. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin. Nephrol. 1990, 1, 162-179.
4. Perico, N.; Benigni, A.; Zoja, C.; Delaini, F.; Remuzzi, G. Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. Am. J. Physiol. 1986, 251, F581-F587.
5. Kon, V.; Sugiura, M.; Inagami, T.; Harvie, B.R.; Ichikawa, I.; Hoover, R.L. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990, 37, 1487-1491.
6. Perico, N.; Zoja, C.; Benigni, A.; Bosco, E.; Rossini, M.; Morelli, C.; Cattaneo, G.M.; Remuzzi, G. Renin-angiotensin system and glomerular prostaglandins in early nephrotoxicity of ciclosporin. Contrib. Nephrol. 1986, 57, 120-125.
7. Diederich, D.; Yang, Z.; Luscher, T.F. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J. Am. Soc. Nephrol. 1992, 2, 1291-1297.
8. Takenaka, T.; Hashimoto, Y.; Epstein, M. Diminished acetylcholine-induced vasodilation in renal microvessels of cyclosporine-treated rats. J. Am. Soc. Nephrol. 1992, 3, 42-50.
9. Darlametsos, I.; Morphake, P.; Bariety, J.; Hornych, A.; Tsipas, G.; Gkikas, G.; Papanikolaou, N. Effect of ketanserin in cyclosporine-induced renal dysfunction in rats. Nephron 1995, 70, 249-254.
10. Mihatsch, M.J.; Thiel, G.; Ryffel, B. Morphology of ciclosporin nephropathy. Prog. Allergy 1986, 38, 447-465.
11. Ryffel, B.; Siegl, H.; Petric, R.; Muller, A.M.; Hauser, R.; Mihatsch, M.J. Nephrotoxicity of cyclosporine in spontaneously hypertensive rats: effects on blood pressure and vascular lesions. Clin. Nephrol. 1986, 25, S193-S198.
12. Ignarro, L.; Murad, F. Nitric Oxide, Biochemistry, Molecular Biology and Therapeutic Implications; Academic Press: San Diego, CA, 1985; 71-85.
13. Misko, T.P.; Moore, W.M.; Kasten, T.P.; Nickols, G.A.; Corbett, J.A.; Tilton, R.G.; McDaniel, M.L.; Williamson, J.R.; Currie, M.G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 1993, 233, 119-125.
14. Bobadilla, N.A.; Tapia, Er, Franco, M.; Lopez, P.; Mendoza, S.; Garcia-Torres, R.; Alvarado, J.A.; Herrera-Acosta, J. Role of nitric oxide in renal hemodynamic abnormalities of cyclosporin nephrotoxicity. Kidney Int. 1994, 46, 773-779.
15. Bobadilla, N.A.; Gamba, G.; Tapia, E.; Garcia-Torres, R.; Bolio, A.; Lopez-Zetina, P.; Herrera-Acosta, J. Role of NO in cyclosporin nephrotoxicity: effects of chronic NO inhibition and NO synthases gene expression. Am. J. Physiol. 1998, 274, F791-F798.
16. Kone, B.C.; Baylis, C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am. J. Physiol. 1997, 272, F561-F578.
17. Marsden, P.A.; Heng, H.H.; Scherer, S.W.; Stewart, R.J.; Hall, A.V.; Shi, X.M.; Tsui, L.C.; Schappert, K.T. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J. Biol. Chem. 1993, 268, 17478-17488.
18. Hogg, N. Free radicals in disease. Semin. Reprod. Endocrimol. 1998, 16, 241-248.
19. Mak, I.T.; Weglicki, W.B. Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ. Res. 1990, 66, 1449-1452.
20. Shridi, F.; Robak, J. The influence of calcium channel blockers on Superoxide anions. Pharmacol. Res. Commun. 1998, 20, 13-21.
21. Janero, D.R.; Burghardt, B. Antiperoxidant effects of dihydropyridine calcium antagonists. Biochem. Pharmacol. 1989, 38, 4344-4348.
22. Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-357.
23. Varley, H. The plasma proteins. In Practical Clinical Biochemistry; Varley, H., Ed.; CBS: Delhi, 1988; 236-238.
24. Chander, V.; Singh, D.; Chopra, K. Attenuation of glycerol-induced acute renal failure in rats by trimetazidine and deferoxamine. Pharmacology 2003, 67, 41-48.
25. Jollow, D.J.; Mitchell, L.R.; Zampaglione, N.; Gillete, J.R. Bromobenze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzeneoxide as the hepatotoxic intermediate. Pharmacology 1974, 11, 151-156.
26. Claiborne, A. CRC Handbook of Methods for Oxygen Radical Reaserch; Greenwald, R.A., Ed.; CRC Press: Boca Raton, FL, 1985; 283-287.
27. Kono, Y. Generation of superoxide radical during autoxidation of hydroxylamine and an assay for superoxide dismutase. Arch. Biochem. Biophys. 1978, 186, 189-195.
28. Zoja, C.; Furci, L.; Ghilardi, F.; Zilio, P.; Benigni, A.; Rerhuzzi, G. Cyclosporin-induced endothelial cell injury. Lab. Invest. 1995, 55, 455-462.
29. Diederich, D.; Skopec, J.; Diederich, A.; Dai, F.X. Cyelpsporine produces endothelial dysfunction by increased production of superoxide. Hypertension 1994, 23, 957-961.
30. Mansour, M.; Daba, M.H.; Gado, A.; Al-Rikabi, A.; Al-Majed, A. Protective effect of L-arginine against nephrotoxicity induced by cyclosporine in normal rats Pharmacol. Res. 2002, 45, 441-446.
31. De Nicola, L.; Thomson, S.C.; Wead, L.M.; Brown, M.R.; Gabbai, F.B. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J. Clin. Invest. 1993, 92, 1859-1865.
32. Andoh, T.F.; Gardner, M.P.; Bennett, W.M. Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997, 64, 1236-1240.
33. Oriji, G.K.; Keiser, H.R. Role of nitric oxide in cyclosporine A-induced hypertension. Hypertension 1998, 32, 849-855.
34. Hofmann, F.; Flockerzi, V.; Nastainczyk, W.; Ruth, P.; Schneider, T. The molecular structure and regulation of muscular calcium channels. Curr. Top. Cell. Regul. 1990, 31, 223-239.
35. Catterall, W.A.; Striessnig, J. Receptor sites for Ca2+ channel antagonists. Trends Pharmacol. Sci. 1992, 13, 256-262.
36. Frishman, W.H. Current status of calcium channel blockers. Curr. Probl. Cardiol. 1994, 19, 637-688.
37. Kojda, G.; Klaus, W.; Werner, G.; Fricke, U. Reduced responses of nitrendipine in PGF2 alpha-precontracted porcine isolated arteries after pretreatment with methylene blue. Basic Res. Cardiol. 1990, 85, 461-466.
38. Colden-Stanfield, M.; Schilling, W.P.; Ritchie, A.K.; Eskin, S.G.; Navarro, L.T.; Kunze, D.L. Bradykinin-induced increases in cytosolic calcium and ionic currents in cultured bovine aortic endothelial cells. Circ. Res. 1987, 61, 632-640.
39. Adams, D.J.; Barakeh, J.; Laskey, R.; Van Breemen, C. Ion channels and regulation of intracellular calcium in vascular endothelial cells. FASEB J. 1989, 3, 2389-2400.
40. Furchgott, R.F.; Zawadzki, J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 27, 373-376.
41. Ignarro, L.J. Endothelium-derived nitric oxide: actions and properties. FASEB J. 1989, 3, 31-36.
42. Salameh, A.; Schomecker, G.; Breitkopf, K.; Dhein, S.; Klaus, W. The effect of the calcium-antagonist nitrendipine on intracellular calcium concentration in endothelial cells. Br. J. Pharmacol. 1996, 118, 1899-1904.
43. Salomone, S.; Morel, N.; Godfraind, T. A therapeutic dosage of amlodipine prevents vascular hyporeactivity induced in rats by lipopolysaccharide. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 357, 252-259.
44. Zhang, X.; Hintze, T.H. Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998, 97, 576-580.
45. Dhein, S.; Zhao, Y.; Simsek, S.; Salameh, A.; Klaus, W. Actions of 1,4-dihydropyridines in isolated mesenteric vascular beds. J. Cardiovasc. Pharmacol. 1995, 26, 784-791.
46. Gunther, J.; Dhein, S.; Rosen, R.; Klaus, W.; Fricke, U. Nitric oxide (EDRF) enhances the vasorelaxing effect of nitrendipine in various isolated arteries. Basic Res. Cardiol. 1992, 87, 452-460.
47. Ding, Y.; Vaziri, N.D. Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension 1998, 32, 718-723.
48. Berkels, R.; Egink, G.; Marsen, T.A.; Bartels, H.; Roesen, R.; Klaus, W. Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001, 37, 240-245.
49. Berkels, R.; Klaus, W.; Boller, M.; Rosen, R. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb. Haemost. 1994, 72, 309-312.
50. 2+ and NO formation in endothelial cells via a kinase dependent mechanism. J. Mol. Cardiol. 1998, 30, A193-A198.
51. Naruse, M.; Tanabe, A.; Seki, T.; Adachi, C.; Yoshimoto, T.; Mishina, N.; Imaki, T.; Naruse, K.; Demura, R.; Demura, H. Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. J. Hypertens. 1999, 17, 53-60.
52. Epstein, M. Calcium antagonists and the kidney. Implications for renal protection. Am. J. Hypertens. 1991, 4, 482S-486S.
53. Arima, S.; Ito, S.; Omata, K.; Tsunoda, K.; Yaoita, H.; Abe, K. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Inter., Suppl. 1996, 55, 132-134.
54. Reiss, W.G.; Bauer, L.A.; Horn, J.R.; Zierler, B.K.; Easterling, T.R.; Strandness, D.E., Jr. The effects of oral nifedipine on hepatic blood flow in humans. Clin. Pharmacol. Ther. 1991, 50, 379-384.
55. Nitsch, J.; Kuhnen, R.; Luderitz, B. Increase in liver circulation with nifedipine. Klin. Wochenschr. 1996, 64, 1113-1118.
56. Ferguson, C.J.; Von Ruhland, C.; Parry-Jones, DJ.; Williams, J.D.; Salaman, J.R. The effects of nifedipine on cyclosporine nephrotoxicity in rats. Transpl. Int. 1992, 5, S490-S493.
57. Wu, W.S.; Yang, C.W.; Bens, M.; Yu, H.M.; Huang, J.Y.; Wu, C.H.; Huang, C.C.; Vandewalle, A. Cyclosporine inhibits nitric oxide production in medullary ascending limb cultured cells. Nephrol. Dial. Transplant. 1998, 13, 2814-2820.